FMR1 and fragile X syndrome: Chronic administration of bryostatin-1 (i.v.)through tail vein for 13 weeks (20 μg/m2, two doses every week), a timescale resembles years of treatment in humans, inhibited hyperactivity of Fmr1 KO mice, a mouse model recapitulating behavioral symptoms of humans with FXS (Cogram et al., 2020).